JHH Prostate Cancer 1999-2004. Prostate Cancer Cases Diagnosed 1999 – 2004 Analytic vs. Non-Analytic n=7776 * Analytic - Initially Diagnosed and/or received.

Slides:

Advertisements

Similar presentations

Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.

Advertisements

The Challenge of Prostate Cancer Genitourinary Cancer Center at M. D. Anderson PERSONALIZED MEDICINE.

Gaurav Agarwal / Jul 2008 SGPGIMS, Lucknow, India Why is SGPGIMS Lucknow an ideal Hospital for state-of-the-art treatment of Breast Cancer.

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Prostate Cancer Cancer: Cancer is a term used for diseases in which abnormal cells divide without control and are able to invade other tissues. Cancer.

Impact of Cancer Diagnosis and Chemotherapy on Mammography Use Xinhua Yu, M.B., Ph.D. A. Marshall McBean, M.D., M.Sc. Beth A. Virnig, Ph.D., M.P.H Division.

Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.

FEMALE BREAST CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/03/20014.

These slides were released by the speaker for internal use by Novartis.

Casefinding & Follow-Up Dolores E. McCord, RHIT, CTR Piedmont Hospital Atlanta, Georgia.

Lung Cancer Emily Cauchon Katie Reeves Emily Cauchon Katie Reeves.

THYROID CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 09/02/2013.

PROSTATE CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 09/01/2013.

MELANOMA JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/16/20014.

2014 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

A Glimpse of the Science Behind the American Cancer Society Access to Care Campaign Impact of Being Uninsured or Underinsured on Individuals with Cancer.

LUNG CANCER Johns Hopkins Hospital Lung Cancer, Non-Small Cell , All Cases n=1364 Analytic - Initially Diagnosed and/or received all.

PANCREATIC CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY 2009.

SEER Provided Data Mohammad Afnan Baqai 12/3/2009.

THYROID CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/16/20014.

Acknowledgements This report differs from the submitted abstract due to further subdivision of patients into analytic and non- analytic, and focus on the.

Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung.

2015 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

1 Sarcoma Ages >= ** Analytic - Initially Diagnosed and/or received all or part of 1st course treatment at.

Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.

Treatment Patterns in the Management of Prostate Cancer: Lessons Learned from the Florida Cancer Data System Vonetta L. Williams, PhD, MPH, CTR June 23,

GASTRIC CANCER JHH Johns Hopkins Hospital Gastric Cancer , All Cases n=317 Analytic - Initially Diagnosed and/or received all or.

ANALYTIC LUNG CANCER by CLASS N = 351 Class 0: Dx’d at JHH only 1: Dx’d at JHH and received all/part of 1st course tx at JHH 2: Dx’d at an outside facility.

Cancer Committee Meeting May 11, 2015 Cancer Liaison Physician Report Karen Lisa Smith MD MPH.

NCDB Report on Breast Cancer at Sibley Cancer Committee Feb Cancer Liaison Physician Karen Lisa Smith MD MPH.

HEAD/NECK CARCINOMA Johns Hopkins Hospital.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Breast Cancer By Amber & Eduardo. Causes Breast Cancer is a disease that Millions of women get diagnosed with every year. Some inherited DNA changes can.

Prostate cancer and ethnicity Luke Hounsome Public Health England.

Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.

Presented at the NAACCR Annual Conference Quebec City June 22, 2010.

Johns Hopkins Hospital Cancer Registry Melanoma

The Role of the HCC Cancer Registry in Facilitating Cancer Research Linda Cope, CTR HCC Registry Coordinator

Lung Cancer Angel.

NON-SMALL CELL LUNG CANCER

JOHNS HOPKINS HOSPITAL CANCER REGISTRY

Johns Hopkins Hospital Malignant and Benign Brain/CNS

JOHNS HOPKINS CANCER REGISTRY 2009

ANALYTIC PANCREATIC CANCER by CLASS N = 369

Johns Hopkins Hospital Cancer Registry

6 Cancer survival Ontario Cancer Statistics 2018 Chapter 6: Cancer survival.

Staging Cancer.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

4 Relative survival Ontario Cancer Statistics 2016 Chapter 4: Relative survival.

People living with AIDS in Maine at the end of 1984

Cancer – advances in treatment and The impact on underwriting and claims Dr. Andreas Armuss.

Evaluate the results of concomitance chemoradiotherapy postoperative treatment for rectal cancer in stage II-III At K Hospital from 2012 to 2016 Speaker:

Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

Lung Cancer (C33-C34): Number and Proportion of Cases Diagnosed at Each Stage, Adults 15-99, Former Anglia Cancer Network Percentage of Total.

4155 primary hepatocellular carcinoma with known diagnosis month/year

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Superior sulcus (Pancoast) tumor: experience with 105 patients

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

Refining esophageal cancer staging

Adjuvant Therapy in Melanoma

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

The Research Question 1) What is the contemporary prevalence of Active Surveillance (AS) adoption among men newly diagnosed with low-risk localized prostate.

Data Analytics course.

Presentation transcript:

JHH Prostate Cancer

Prostate Cancer Cases Diagnosed 1999 – 2004 Analytic vs. Non-Analytic n=7776 * Analytic - Initially Diagnosed and/or received all or part of 1st course treatment at JHH **Non-Analytic - Initially diagnosed & treated elsewhere to JHH for treatment of recurrent, metastatic or progression of disease.

Prostate Cancer Cases Diagnosed 1999 – 2004 All Cases Age at Diagnosis n=7776

Prostate Cancer Cases Diagnosed 1999 – 2004 All Cases by Race n=7776

Prostate Cancer Cases Diagnosed 1999 – 2004 All Cases by Maryland Counties n=2585

Prostate Cancer Cases Diagnosed 1999 – 2004 All Cases by State n=7776

Johns Hopkins Hospital Prostate Cancer Stage at Diagnosis, Analytic n=7463

Prostate Cancer Cases Diagnosed 1999 – 2004 All Cases by Treatment, Analytic n=7238

Prostate Cancer Cases Diagnosed 2000 – 2001 Treatment by AJCC Stage, Class 1 and 2 AJCC I Percentage % Maryland (n=173)JHH (n=47)National (n=5869) Surgery Only Radiation Only Surgery & Radiation 000 Surgery, Radiation, Hormone Therapy 000 Radiation & Hormone Therapy Surgery & Hormone Therapy 000 Hormone Therapy Only Other Specified Therapy (JHH other is WW) No Treatment TOTAL 100

Prostate Cancer Cases Diagnosed 2000 – 2001 Treatment by AJCC Stage, Class 1 and 2 AJCC II Percentage % Maryland (n=5097)JHH (n=1766)National (n=178413) Surgery Only Radiation Only Surgery & Radiation Surgery, Radiation, Hormone Therapy 000 Radiation & Hormone Surgery & Hormone Therapy Hormone Therapy Only Other Specified Therapy No Treatment TOTAL 100

Prostate Cancer Cases Diagnosed 2000 – 2001 Treatment by AJCC Stage, Class 1 and 2 AJCC III Percentage % Maryland (n=798)JHH (n=547)National (n=19151) Surgery Only Radiation Only Surgery & Radiation Surgery, Radiation, Hormone Radiation & Hormone Surgery & Hormone Therapy Hormone Therapy Only Other Specified Therapy No Treatment 000 TOTAL 100

Prostate Cancer Cases Diagnosed 2000 – 2001 Treatment by AJCC Stage, Class 1 and 2 AJCC IV Percentage % Maryland (n=285)JHH (n=74)National (n=12075) Surgery Only *15.3 Radiation Only Surgery & Radiation 000 Surgery, Radiation, Hormone Therapy Radiation & Hormone Therapy Surgery & Hormone Therapy Hormone Therapy Only Other Specified Therapy No Treatment TOTAL 100

Prostate Cancer Cases Diagnosed 2000 – 2001 Treatment by AJCC Stage, Class 1 and 2 AJCC IV AJCC Edition 5 (1998 – 2002) Stage IV Includes T4 N0 M0 – (3 cases) Any T N1 M0 T2 N1 M0 – (2 cases) T2a N1 M0 - (2 cases) T3a N1 M0 – (12 cases) T3b N1 M0 - (17 cases) T4 N1 M0 – (1 cases) Any T Any N M1 – (37 cases)

Prostate Cancer Cases Diagnosed 1995 – 1996 Treatment by AJCC Stage, Class 1 and 2 AJCC IV AJCC Edition 4 Stage IV Includes T4 N0 M0 – (12 cases) Any T N1 M0 (44 cases) Any T N2 M0 (12 cases) Any TN3 M0 (1 case) Any T Any N M1 – (23 cases)

Observed Five Year Survival Rates for Prostate Cancer Cases Diagnosed 1995 and 1996 Source: NCDB, CoC, ACoS/ACS Survival Reports, v2.0

Observed Five Year Survival Rates for Prostate Cancer Cases Diagnosed 1995 and 1996 Source: NCDB, CoC, ACoS/ACS Survival Reports, v2.0

Observed Five Year Survival Rates for Prostate Cancer Cases Diagnosed 1995 and 1996 Source: NCDB, CoC, ACoS/ACS Survival Reports, v2.0

Observed Five Year Survival Rates for Prostate Cancer Cases Diagnosed 1995 and 1996 Source: NCDB, CoC, ACoS/ACS Survival Reports, v2.0